Catheter Precision Inc (VTAK) concluded trading on Wednesday at a closing price of $0.45, with 4.63 million shares of worth about $2.09 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -85.84% during that period and on January 15, 2025 the price saw a loss of about -5.67%. Currently the company’s common shares owned by public are about 8.00M shares, out of which, 7.50M shares are available for trading.
Stock saw a price change of -20.92% in past 5 days and over the past one month there was a price change of 20.48%. Year-to-date (YTD), VTAK shares are showing a performance of -1.11% which decreased to -88.63% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.31 but also hit the highest price of $8.40 during that period. The average intraday trading volume for Catheter Precision Inc shares is 3.72 million. The stock is currently trading 3.43% above its 20-day simple moving average (SMA20), while that difference is up 3.92% for SMA50 and it goes to -81.37% lower than SMA200.
Catheter Precision Inc (AMEX: VTAK) currently have 8.00M outstanding shares and institutions hold larger chunk of about 2.02% of that.
The stock has a current market capitalization of $3.57M and its 3Y-monthly beta is at -0.37. It has posted earnings per share of -$12.13 in the same period. It has Quick Ratio of 0.65 while making debt-to-equity ratio of 0.91. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for VTAK, volatility over the week remained 16.46% while standing at 15.00% over the month.
Analysts are in expectations that Catheter Precision Inc (VTAK) stock would likely to be making an EPS of -0.2 in the current quarter, while forecast for next quarter EPS is -0.2 and it is -0.63 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.2 which is -0.2 at the higher side of the target for the same. Stock’s fiscal year EPS is expected to rise by 93.15% while it is estimated to increase by 29.21% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Piper Jaffray on August 13, 2019 offering a Neutral rating for the stock and assigned a target price range of between $9 and $1.50 to it. Coverage by Maxim Group stated Catheter Precision Inc (VTAK) stock as a Buy in their note to investors on November 02, 2018, suggesting a price target of $23 for the stock.
